
Athira Pharma ATHA
Quartalsbericht 2025-Q3
hinzugefügt 06.11.2025
Athira Pharma Betriebsaufwand 2011-2026 | ATHA
Betriebsaufwand Jährlich Athira Pharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 18.7 M | 4.7 M | 5.01 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 18.7 M | 4.7 M | 9.46 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | ||
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M | ||
|
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | ||
|
ANI Pharmaceuticals
ANIP
|
127 M | $ 80.34 | -1.83 % | $ 1.55 B | ||
|
Aptorum Group Limited
APM
|
20.7 M | $ 0.84 | 3.54 % | $ 4.58 M | ||
|
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | ||
|
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.57 | 1.13 % | $ 8.59 B | ||
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | ||
|
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | ||
|
BioNTech SE
BNTX
|
512 M | $ 110.34 | 3.49 % | $ 27.2 B | ||
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | ||
|
Cabaletta Bio
CABA
|
74.7 M | $ 2.44 | -2.79 % | $ 2.85 M | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 4.22 | 1.44 % | $ 9.18 B | ||
|
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
167 M | $ 1.5 | 7.91 % | $ 281 M | ||
|
Aptose Biosciences
APTO
|
26.3 M | - | -45.71 % | $ 1.2 M | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
338 M | $ 222.03 | -0.05 % | $ 5 B | ||
|
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | ||
|
Compugen Ltd.
CGEN
|
40.4 M | $ 1.71 | 2.4 % | $ 153 M | ||
|
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | ||
|
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | ||
|
Burford Capital Limited
BUR
|
106 M | $ 8.97 | 0.56 % | $ 1.43 B | ||
|
Aridis Pharmaceuticals
ARDS
|
23.4 K | - | 17.91 % | $ 11.1 M | ||
|
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
189 M | $ 41.31 | 1.18 % | $ 4.26 B | ||
|
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | ||
|
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
190 M | $ 24.45 | 0.04 % | $ 2.9 B | ||
|
Cardiff Oncology
CRDF
|
49.3 M | $ 1.58 | -1.25 % | $ 75.3 M | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
CRISPR Therapeutics AG
CRSP
|
504 M | $ 49.7 | 1.97 % | $ 4.19 B | ||
|
Champions Oncology
CSBR
|
12.5 M | $ 6.55 | - | $ 89.5 M | ||
|
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.46 | 2.82 % | $ 373 M | ||
|
Amneal Pharmaceuticals
AMRX
|
539 M | $ 14.52 | - | $ 4.49 B |